Schedule of Investments
ARK Genomic Revolution ETF
April 30, 2022 (Unaudited)
Investments | Shares | Value | ||||||
COMMON STOCKS–99.7% | ||||||||
Biotechnology - 56.8% | ||||||||
Arcturus Therapeutics Holdings, Inc.*† | 2,290,931 | $ | 44,398,243 | |||||
Beam Therapeutics, Inc.* | 2,048,042 | 76,863,016 | ||||||
Burning Rock Biotech Ltd. (China)*(a) | 3,383,088 | 18,640,815 | ||||||
CareDx, Inc.*† | 3,370,274 | 102,591,140 | ||||||
CRISPR Therapeutics AG (Switzerland)* | 1,888,742 | 93,719,378 | ||||||
Editas Medicine, Inc.* | 505,580 | 6,693,879 | ||||||
Exact Sciences Corp.* | 4,335,503 | 238,669,440 | ||||||
Fate Therapeutics, Inc.* | 4,274,721 | 122,086,032 | ||||||
Incyte Corp.* | 1,211,858 | 90,840,876 | ||||||
Intellia Therapeutics, Inc.* | 1,780,643 | 87,304,926 | ||||||
Ionis Pharmaceuticals, Inc.* | 5,927,986 | 217,912,765 | ||||||
Iovance Biotherapeutics, Inc.* | 2,918,768 | 44,219,335 | ||||||
Nurix Therapeutics, Inc.* | 774,008 | 8,568,268 | ||||||
Organovo Holdings, Inc.* | 194,811 | 559,108 | ||||||
Recursion Pharmaceuticals, Inc., Class A* | 2,716,603 | 16,842,939 | ||||||
Regeneron Pharmaceuticals, Inc.* | 55,399 | 36,514,035 | ||||||
Repare Therapeutics, Inc. (Canada)*† | 2,763,704 | 30,400,744 | ||||||
Surface Oncology, Inc.*† | 5,568,289 | 11,804,773 | ||||||
Twist Bioscience Corp.* | 2,203,119 | 63,537,952 | ||||||
Veracyte, Inc.* | 1,941,565 | 39,743,835 | ||||||
Vertex Pharmaceuticals, Inc.* | 368,289 | 100,623,921 | ||||||
Verve Therapeutics, Inc.* | 1,621,064 | 24,186,275 | ||||||
Total Biotechnology | 1,476,721,695 | |||||||
Chemicals - 2.4% | ||||||||
Ginkgo Bioworks Holdings, Inc.* | 19,633,360 | 56,936,744 | ||||||
Zymergen, Inc.* | 3,015,560 | 5,066,141 | ||||||
Total Chemicals | 62,002,885 | |||||||
Electronic Equipment, Instruments & Components - 2.5% | ||||||||
908 Devices, Inc.*† | 3,606,201 | 64,010,068 | ||||||
Financial Services - 0.8% | ||||||||
Dynamics Special Purpose Corp., Class A*† | 2,189,888 | 21,679,891 | ||||||
Health Care Equipment & Supplies - 1.6% | ||||||||
Butterfly Network, Inc.* | 7,053,462 | 23,488,028 | ||||||
Cerus Corp.* | 4,218,000 | 19,487,160 | ||||||
Total Health Care Equipment & Supplies | 42,975,188 | |||||||
Health Care Providers & Services - 8.3% | ||||||||
1Life Healthcare, Inc.* | 5,766,328 | 40,652,612 | ||||||
Accolade, Inc.*† | 6,212,573 | 34,541,906 | ||||||
Castle Biosciences, Inc.* | 1,076 | 24,038 | ||||||
Invitae Corp.* | 5,547,683 | 29,458,197 | ||||||
Signify Health, Inc., Class A* | 8,052,596 | 111,125,825 | ||||||
Total Health Care Providers & Services | 215,802,578 | |||||||
Health Care Technology - 9.4% | ||||||||
Schrodinger, Inc.* | 2,722,677 | 67,304,576 | ||||||
Teladoc Health, Inc.* | 3,919,836 | 132,333,663 | ||||||
Veeva Systems, Inc., Class A* | 240,683 | 43,792,272 | ||||||
Total Health Care Technology | 243,430,511 | |||||||
Life Sciences Tools & Services - 14.2% | ||||||||
10X Genomics, Inc., Class A* | 527,710 | 25,203,430 | ||||||
Adaptive Biotechnologies Corp.*† | 7,407,963 | 61,115,695 | ||||||
Berkeley Lights, Inc.* | 3,278,333 | 16,309,707 | ||||||
Codexis, Inc.*† | 3,787,753 | 45,566,668 | ||||||
Compugen Ltd. (Israel)* | 3,086,693 | 7,346,329 | ||||||
Pacific Biosciences of California, Inc.*† | 12,161,292 | 77,102,591 | ||||||
Personalis, Inc.*† | 5,315,226 | 29,765,266 | ||||||
Quantum-Si, Inc.*† | 11,796,144 | 51,667,111 | ||||||
SomaLogic, Inc.* | 8,781,286 | 55,497,727 | ||||||
Total Life Sciences Tools & Services | 369,574,524 | |||||||
Pharmaceuticals - 1.6% | ||||||||
ATAI Life Sciences NV (Germany)* | 1,608,832 | 6,901,889 | ||||||
Pfizer, Inc. | 729,647 | 35,803,779 | ||||||
Total Pharmaceuticals | 42,705,668 | |||||||
Software - 2.1% | ||||||||
UiPath, Inc., Class A* | 3,116,115 | 55,560,330 | ||||||
Total Common Stocks (Cost $7,289,836,532) | 2,594,463,338 | |||||||
MONEY MARKET FUND–0.4% | ||||||||
Dreyfus Government Cash Management Fund, Institutional Shares, 0.24% (b) (Cost $10,640,346) | 10,640,346 | 10,640,346 | ||||||
Total Investments–100.1% (Cost $7,300,476,878) | 2,605,103,684 | |||||||
Liabilities in Excess of Other Assets–(0.1)% | (3,387,967 | ) | ||||||
Net Assets–100.0% | $ | 2,601,715,717 |
Schedule of Investments (continued)
ARK Genomic Revolution ETF
April 30, 2022 (Unaudited)
Affiliated Issuer Transactions
A summary of the Fund’s period to date transactions with companies which are or were affiliated issuers during the period are as follows:
Value ($) at 7/31/2021 | Purchases Cost ($) | Sales Proceeds ($) | Net Realized Gain/(Loss) ($) | Net Change in Unrealized Appreciation (Depreciation) ($) | Dividend Income ($) | Capital Gain Distributions ($) | Number of Shares at 4/30/2022 | Value ($) at 4/30/2022 | |||||||||||||||||||||||||
Common Stocks — 22.1% | |||||||||||||||||||||||||||||||||
Biotechnology — 7.3% | |||||||||||||||||||||||||||||||||
AquaBounty Technologies, Inc. | |||||||||||||||||||||||||||||||||
32,699,225 | 4,009,148 | (16,947,273 | ) | (29,687,800 | ) | 9,926,700 | – | – | – | – | |||||||||||||||||||||||
Arcturus Therapeutics Holdings, Inc. | |||||||||||||||||||||||||||||||||
84,888,987 | 48,098,552 | (59,684,891 | ) | 10,117,343 | (39,021,748 | ) | – | – | 2,290,931 | 44,398,243 | |||||||||||||||||||||||
CareDx, Inc. | |||||||||||||||||||||||||||||||||
310,172,395 | 112,267,697 | (121,606,843 | ) | (993,044 | ) | (197,249,065 | ) | – | – | 3,370,274 | 102,591,140 | ||||||||||||||||||||||
Cellectis SA | |||||||||||||||||||||||||||||||||
56,897,431 | 8,557,317 | (37,117,817 | ) | (67,316,016 | ) | 38,979,085 | – | – | – | – | |||||||||||||||||||||||
Evogene Ltd. | |||||||||||||||||||||||||||||||||
9,030,619 | 1,370,733 | (5,974,805 | ) | (1,103,073 | ) | (3,323,474 | ) | – | – | – | – | ||||||||||||||||||||||
Fate Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
357,383,678 | 165,310,458 | (155,251,465 | ) | (23,239 | ) | (245,333,400 | ) | – | – | – | – | ||||||||||||||||||||||
Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
335,200,942 | 111,151,766 | (212,048,847 | ) | (46,520,788 | ) | 30,129,692 | – | – | – | – | |||||||||||||||||||||||
Repare Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
93,387,201 | 45,298,482 | (42,743,095 | ) | (3,010,868 | ) | (62,530,976 | ) | – | – | 2,763,704 | 30,400,744 | ||||||||||||||||||||||
Surface Oncology, Inc. | |||||||||||||||||||||||||||||||||
26,008,455 | 25,837,322 | (17,219,276 | ) | (1,440,646 | ) | (21,381,082 | ) | – | – | 5,568,289 | 11,804,773 | ||||||||||||||||||||||
Twist Bioscience Corp. | |||||||||||||||||||||||||||||||||
303,792,362 | 85,020,415 | (122,804,728 | ) | 6,908,228 | (209,378,325 | ) | – | – | – | – | |||||||||||||||||||||||
Electronic Equipment, Instruments & Components — 2.5% | |||||||||||||||||||||||||||||||||
908 Devices, Inc. | |||||||||||||||||||||||||||||||||
81,883,531 | 72,922,293 | (49,086,120 | ) | (557,950 | ) | (41,151,686 | ) | – | – | 3,606,201 | 64,010,068 | ||||||||||||||||||||||
Financial Services — 0.8% | |||||||||||||||||||||||||||||||||
Dynamics Special Purpose Corp. | |||||||||||||||||||||||||||||||||
19,718,888 | 13,506,336 | (11,624,755 | ) | (17,030 | ) | 96,452 | – | – | 2,189,888 | 21,679,891 | |||||||||||||||||||||||
Health Care Providers & Services — 1.3% | |||||||||||||||||||||||||||||||||
Accolade, Inc. | |||||||||||||||||||||||||||||||||
259,620,477 | 79,603,469 | (92,908,679 | ) | (16,081,989 | ) | (195,691,372 | ) | – | – | 6,212,573 | 34,541,906 | ||||||||||||||||||||||
Castle Biosciences, Inc. | |||||||||||||||||||||||||||||||||
156,646,658 | 27,282,782 | (108,428,616 | ) | (73,103,931 | ) | (2,372,855 | ) | – | – | – | – | ||||||||||||||||||||||
Signify Health, Inc. | |||||||||||||||||||||||||||||||||
139,077,091 | 165,171,256 | (91,224,997 | ) | (4,764,908 | ) | (97,132,617 | ) | – | – | – | – | ||||||||||||||||||||||
Life Sciences Tools & Services — 10.2% | |||||||||||||||||||||||||||||||||
Adaptive Biotechnologies Corp. | |||||||||||||||||||||||||||||||||
153,890,542 | 164,031,814 | (90,745,580 | ) | (2,340,927 | ) | (163,720,154 | ) | – | – | 7,407,963 | 61,115,695 | ||||||||||||||||||||||
Berkeley Lights, Inc. | |||||||||||||||||||||||||||||||||
145,389,853 | 53,105,066 | (39,355,971 | ) | (10,191,463 | ) | (132,637,778 | ) | – | – | – | – | ||||||||||||||||||||||
Codexis, Inc. | |||||||||||||||||||||||||||||||||
135,791,147 | 54,737,422 | (140,840,098 | ) | 26,784,706 | (30,906,509 | ) | – | – | 3,787,753 | 45,566,668 | |||||||||||||||||||||||
Pacific Biosciences of California, Inc. | |||||||||||||||||||||||||||||||||
460,481,139 | 129,552,825 | (169,225,982 | ) | 113,015,002 | (456,720,393 | ) | – | – | 12,161,292 | 77,102,591 | |||||||||||||||||||||||
Personalis, Inc. | |||||||||||||||||||||||||||||||||
97,468,702 | 59,214,298 | (46,708,296 | ) | (2,928,813 | ) | (77,280,625 | ) | – | – | 5,315,226 | 29,765,266 | ||||||||||||||||||||||
Quantum-Si, Inc. | |||||||||||||||||||||||||||||||||
71,309,635 | 82,833,490 | (48,078,385 | ) | (936,040 | ) | (53,461,589 | ) | – | – | 11,796,144 | 51,667,111 | ||||||||||||||||||||||
Molecular Diagnostics — 0.0% | |||||||||||||||||||||||||||||||||
CM Life Sciences II, Inc. | |||||||||||||||||||||||||||||||||
32,363,829 | 1,149,934 | (1,108,561 | ) | (144,970 | ) | 5,547,068 | – | – | – | – | |||||||||||||||||||||||
$3,363,102,787 | $ | 1,510,032,875 | $ | (1,680,735,080 | ) | $ | (104,338,216 | ) | $ | (1,944,614,651 | ) | $ | – | $ | – | 66,470,238 | $ | 574,644,096 |
† | Affiliated security |
* | Non-income producing security |
(a) | American Depositary Receipt |
(b) | Rate shown represents annualized 7-day yield as of April 30, 2022. |
Schedule of Investments (continued)
ARK Genomic Revolution ETF
April 30, 2022 (Unaudited)
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
• Level 1 — Quoted prices in active markets for identical assets.
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
• Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of April 30, 2022, based upon the three levels defined above:
ARK Genomic Revolution ETF | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Assets | ||||||||||||||||
Common Stocks‡ | $ | 2,594,463,338 | $ | – | $ | – | $ | 2,594,463,338 | ||||||||
Money Market Fund | 10,640,346 | – | – | 10,640,346 | ||||||||||||
Total | $ | 2,605,103,684 | $ | – | $ | – | $ | 2,605,103,684 |
‡ | Please refer to the Schedule of Investments to view securities segregated by industry type. |